Society Of Urologic Oncology Meeting - Renal Carcinoma - Management Of The Small Renal Mass - Evolving Role Of Needle Biopsy In 2008 And Beyond

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials;  Conferences
Article Date: 31 May 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - Dr. David Wood discussed the role of renal mass biopsy. He presented a case of a 65 year old man with metastatic prostate cancer as compared to a 65 year old man with a 2.7cm exophytic solid renal mass. The likelihood of renal cancer is 72% in this setting. Yet most would biopsy the man with likely prostate cancer but not the patient with the renal mass. This is because, as some would argue, that the biopsy is not accurate. He showed data that an 18 gauge core biopsy is between 96% and 100% accurate. Tumor seeding risk is <0.01% and thus not an issue.

Pathologists can accurately establish a tumor grade and histologic type. The sensitivities of renal biopsies are 86-100% and specificity is 97-100%. Also, sufficient tissue is obtained in 98%. In the Michigan series, benign pathology was found in up to 35%. While some might argue that the biopsy pathology would not change treatment, Dr. Wood stated that up to 40% of the time it would change treatment due to the large number of benign lesions.

Presented by David Wood, Jr., MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations